Results 211 to 220 of about 36,119 (263)

European Medicines Agency approvals of new medicines in September and October 2025. [PDF]

Lancet Reg Health Eur
Sepodes B, Burgos JG, Thirstrup S.
europepmc   +1 more source

Cardiovascular adverse events associated with denosumab versus zoledronic acid in patients with breast cancer: a propensity score overlap weighted analysis. [PDF]

Breast Cancer Res Treat
Iwai C, Konishi T, Miyawaki A, Okada A, Isogai T, Jo T, Yasunaga H.   +6 more
europepmc   +1 more source

Follow-on osteoporosis therapy after denosumab discontinuation among Medicare beneficiaries. [PDF]

Osteoporos Int
Sendhil SR, Cadarette SM, Aggarwal S, Oganisian A, Zullo AR, Berry SD, Adegboye MA, Hayes KN.   +7 more
europepmc   +1 more source

Metachronous multicentric giant cell tumor of bone treated with denosumab and mega-prosthesis revision: a rare case report. [PDF]

Front Oncol
Lin H, Yang C, Zhu J, Yang C, Xu Z, Wu Z, Wang X, Wang W.   +7 more
europepmc   +1 more source

Pharmacokinetics and pharmacodynamics of the denosumab biosimilar FKS518 and reference denosumab in healthy subjects: the Lumiade-1 study. [PDF]

JBMR Plus
Dryja A, Cieślak M, Sobieraj P, Szeles P, de Souza ALS, Monnet J.   +5 more
europepmc   +1 more source

Analysis of the efficacy and safety of denosumab in the treatment of patients with osteoporotic vertebral compression fractures after PVP. [PDF]

Sci Rep
Jiang Y, He B, Shang Q, Liu H, Chen W, Zhao W, Shen G, Ren H, Jiang X.   +8 more
europepmc   +1 more source

Efficacy of denosumab versus alendronate for aromatase inhibitor-associated osteoporosis in postmenopausal breast cancer patients: a retrospective analysis. [PDF]

BMC Musculoskelet Disord
Zhang Y, Cui W, Hou L.
europepmc   +1 more source

Chronic kidney disease and denosumab in metastatic bone disease: A multicenter Turkish cohort study on severe hypocalcemia, skeletal events, and survival. [PDF]

J Bone Oncol
Ellez Hİ, Semiz HS, Ekinci F, Erdoğan AP, Kuş F, Karataş F, Bayram E, Karaboyun K, Çınkır HY, Yıldırım N, Eryılmaz MK, Bekmez ET, Alan Ö, Özçelik M, Düzköprü Y, Şakalar T, Ak N, İlhan Y, Yavuzşen T, Turhal NS.   +19 more
europepmc   +1 more source

Denosumab as a Potential Disease-Modifying Treatment in Indolent Systemic Mastocytosis-Related Osteoporosis. [PDF]

JCEM Case Rep
Abbas M, Luthra P.
europepmc   +1 more source